Predictive Oncology (NASDAQ:POAI) Downgraded to “Strong Sell” Rating by Wall Street Zen

Predictive Oncology (NASDAQ:POAI) was downgraded by research analysts at Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Predictive Oncology in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Predictive Oncology Price Performance

Shares of NASDAQ POAI opened at $4.26 on Friday. The company has a 50-day moving average price of $9.01 and a 200-day moving average price of $11.85. The stock has a market capitalization of $14.44 million, a P/E ratio of -0.32 and a beta of 1.35. Predictive Oncology has a 1 year low of $3.88 and a 1 year high of $45.90.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings results on Friday, November 14th. The medical instruments supplier reported ($4.52) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($3.17). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $1.50 million. Predictive Oncology had a negative net margin of 5,065.23% and a negative return on equity of 732.73%. As a group, equities research analysts anticipate that Predictive Oncology will post -2.08 earnings per share for the current fiscal year.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.